Therapeutic options in advanced prostate cancer: Present and future Journal Articles

abstract

• Patients with advanced prostate cancer now have many treatment options available including first- and second-line hormonal therapy, radiotherapy, bisphosphonate therapy with zoledronic acid, and taxane-based chemotherapy. These options now give clinicians an opportunity to offer their patients symptomatic relief and most importantly improve overall survival. This article reviews the current treatment options available for men with advanced prostate cancer. In addition, novel treatment options under development, including calcitriol, immunotherapies, small molecule inhibitors, and nucleotide-based targeted therapy, are discussed.

authors

• Sowery, Richard
• So, Alan I
• Gleave, Martin E

status

• published 

publication date

• January 2007

has subject area

• Androgen Antagonists (MeSH)
• Antineoplastic Agents, Hormonal (MeSH)
• Brachytherapy (MeSH)
• Calcitriol (MeSH)
• Cancer Vaccines (MeSH)
• Combined Modality Therapy (MeSH)
• Forecasting (MeSH)
• Humans (MeSH)
• Immunotherapy (MeSH)
• Male (MeSH)
• Neoplasm Staging (MeSH)
• Prostatic Neoplasms (MeSH)
• Risk Assessment (MeSH)
• Survival Analysis (MeSH)
• Treatment Outcome (MeSH)
• Urology & Nephrology (Science Metrix)

published in

• Current Urology Reports  Journal

keywords

• Androgen Antagonists
• Antineoplastic Agents, Hormonal
• Brachytherapy
• Calcitriol
• Cancer Vaccines
• Combined Modality Therapy
• Forecasting
• Humans
• Immunotherapy
• Male
• Neoplasm Staging
• Prostatic Neoplasms
• Risk Assessment
• Survival Analysis
• Treatment Outcome

Digital Object Identifier (DOI)

• 10.1007/s11934-007-0021-9

PubMed ID

• 17239317

start page

• 53

end page

• 59

volume

• 8

issue

• 1